“We reported total revenue of $2.9 billion, a 29% increase year-over-year.” (CEO)
“Our team is rightsizing the cost of the business in the back half of this year. … We expect these actions will eliminate approximately $60 million in administrative costs for 2026.” (CEO)
“We resubmitted 2026 rate filings in states covering nearly all current membership to reflect morbidity increases.” (CEO)
“We expect the market will have double-digit rate increases next year.” (CEO)
“We are taking appropriate actions to return to profitability in 2026.” (CFO)
Q&A Batch (1-5 of 5)
Q1 — Joshua Richard Raskin
Topic: 2025年自由现金流指引及风险调整应付变动
Key points:
总现金及投资54亿美元，超额资本5.79亿美元，母公司现金2.05亿美元
超额资本环比减少约3亿美元（Q2亏损吸收）
母公司现金下半年将下降（因向子公司注资）
风险调整应付将由表格披露，2025年应付占收入比例低于2024年（仅调整影响）
Mgmt stance: bullish（资本状况强劲，超额资本足以覆盖剩余亏损）
Q2 — Hua Ha
Topic: 多年盈利杠杆及2025年风险池下行风险
Key points:
欺诈/浪费/滥用、PBM重新谈判、ICHRA仍为长期杠杆；AI已用于行政成本削减，正部署临床领域Agentic AI